Coronavirus information for Feinberg.

Skip to main content

Infectious Diseases Clinical Trials

The following searchable list includes all the Division of Infectious Diseases - Department of Medicine clinical trials currently looking for participants. Please feel free to contact us with inquiries about any of our ongoing research.

Trials
Randomized Trial to Prevent Vascular Events in HIV – REPRIEVE (A5332)/ A5333s: Effects of Pitavastatin on Coronary Artery Disease and Inflammatory Biomarkers: Mechanistic Substudy of REPRIEVE/A5361s: Pitavastatin to REduce Physical Function Impairment and Frailty in HIV (PREPARE)
People infected wi…
People infected with HIV are at risk for cardiovascular disease (CVD). REPRIEVE is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months. The trial is testing the effect of statin therapy on preventing heart disease and death in HIV-infected persons on HIV medications who do not meet guidelines for starting statins. HIV causes inflammation (irritation) inside the body that may contribute to diseases such as heart disease. HIV medications can lower inflammation, however the levels of inflammation can remain higher compared to people who are not infected with HIV. Statins, such as pitavastatin, are medications that are used to lower the levels of cholesterol and triglycerides (fat in the blood) and have been shown to lower levels of inflammation and heart disease.
• HIV infected men and women between the ages of 40 and 75
• On anti-HIV medications for at least 6 months
• CD4 cell count greater than 100
• No history of cardiovascular disease, such as heart attack, stroke, etc.
• No history of cancer in the last 3 years
• Not currently using a statin drug
Taiwo, Babafemi OTaiwo, Babafemi O
NCT02344290 STU00200323
More Info
Copy
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults
ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir in adult patients ho…
ACTT-4 will evaluate the combination of baricitinib and remdesivir compared to dexamethasone and remdesivir in adult patients hospitalized with COVID-19 and requiring supplemental oxygen administered by low flow, high flow, or non-invasive mechanical ventilation. 

Hospitalized adults (>18 years) with symptoms suggestive of COVID-19

Illness of any duration and laboratory-confirmed SARS-CoV-2 infection within 14 days

Requires low or high flow oxygen devices or non-invasive mechanical ventilation

Has not received 5 or more doses of remdesivir as treatment for COVID-19

Has not receive 6mg or more of dexamethasone in one day, on more than one day in the past 7 days

Taiwo, Babafemi OTaiwo, Babafemi O
  • Map it 201 E. Huron St.
    Chicago, IL
NCT04280705 STU00212207
More Info
Copy
ACTIV-2/A5401: Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)

ACTIV-2/A5401 is a master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with COVID-19.

This study is being done …

ACTIV-2/A5401 is a master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with COVID-19.

This study is being done to rapidly and efficiently evaluate multiple potential therapeutics for COVID-19 in an outpatient setting.

Duration of study: 28 days of intensive follow-up, followed by limited follow-up through 24 weeks.

  • Outpatient (non-hospitalized) adult (18 years or older)
  • Positive COVID-19 test within 10 days prior to Entry
  • Onset of at least one typical COVID-19 symptom no more than 10 days prior to Entry, plus one the following symptoms present within 24 hours of entry:

–Fever or feeling feverish, cough, shortness of breath, sore throat, body or muscle pain, fatigue, headache,chills, nasal discharge or congestion, loss of taste or smell, nausea or vomiting, diarrhea

Taiwo, Babafemi OTaiwo, Babafemi O
  • Map it 201 E. Huron St.
    Chicago, IL
NCT04518410 STU00213144
More Info
COVID outpatient
Copy